Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mayo Clinic

Latest From Teva Women's Health Inc.

Medtech In Politics: A Look At Republican And Democratic Party Platforms

The Republican presidential platform bashes the US FDA for "chilling and killing" development of new devices, pledging to restore the agency as a leader in medical innovation, while the Democratic Party platform focuses on supporting public health options, including higher funding levels to fight the Zika virus. The two platforms also diverge on tax and trade policy.

United States Regulation

In Brief: NAD Decisions, Warning Letters, EC Law Struck, “Natural” Claims Suit

Pharmavite discontinues ads; NAD looks at supplement concussion claims; FDA warns product requires NDI; Spinal Touch Formulas are unapproved new drugs – FDA; Weight-loss products unapproved, misbranded; Oklahoma law restricting contraception knocked down; and Hammer Nutrition sued over “natural” claims

Consumer United States

Court Order Could Convolute Emergency Contraception Market

A federal appeals court mandates full OTC sales of two-tablet levonorgestrel products, as requested in a 2001 citizen petition. The order delineates two-dose emergency contraceptives from Teva’s Plan B One-Step product, which did not exist at the time of the petition.

Consumer Life Cycle Management

Full OTC Status For Two-Dose Emergency Contraceptives – Appellate Court

Consumer United States
See All